To say whether U.S. regulators will require heart monitoring after the first dose of Arena Pharmaceuticals Inc.'s etrasimod for ulcerative colitis (UC) would be "prognosticating a bit in terms of what the FDA is going to choose to do," said Chief Medical Officer (CMO) Preston Klassen, who refused such guesswork.